Changing T-cell enigma: Cancer killing or cancer control?

Cell Cycle

Volumn 12, Issue 19, 2013, Pages 3335-3342

  Wieder, Thomas ^a   Braumüller, Heidi ^a   Brenner, Ellen ^a   Zender, Lars ^a   Röcken, Martin ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cancer therapy; Cell cycle control; Growth arrest; Immune therapy; Interferon ?; P16Ink4a; Senescence; Thelper 1 cells; Tumor dormancy; Tumor necrosis factor

Indexed keywords

CHEMOKINE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB EMTANSINE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

ANTIGEN PRESENTING CELL; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL STRESS; CELLULAR IMMUNITY; CYTOTOXIC LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA DAMAGE; FEEDBACK SYSTEM; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; LYMPH NODE METASTASIS; LYMPHOMA; METASTATIC MELANOMA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SENESCENCE; T LYMPHOCYTE; TH1 CELL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALIA;

CANCER THERAPY; CELL CYCLE CONTROL; GROWTH ARREST; IMMUNE THERAPY; INTERFERON-Γ; P16INK4A; SENESCENCE; T HELPER-1 CELLS; TUMOR DORMANCY; TUMOR NECROSIS FACTOR;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL AGING; CELL CYCLE CHECKPOINTS; CHEMOKINES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INTERFERON-GAMMA; NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886678117     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26060     Document Type: Review

References (59)

1. Pantel K, Alix-Panabières C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009; 6:339- 51; PMID:19399023; http://dx.doi.org/10.1038/ nrclinonc.2009.44
2. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, Tan TG, Zheng L, Ong LC, Jin Y, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010; 120:2030- 9; PMID:20501944; http://dx.doi.org/10.1172/JCI42002
3. Röcken M. Early tumor dissemination, but late metastasis: insights into tumor dormancy. J Clin Invest 2010; 120:1800-3; PMID:20501952; http://dx.doi.org/10.1172/JCI43424
4. Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494:361-5; PMID:23376950; http://dx.doi.org/10.1038/nature11824
5. Halsted WS. I. The Results of Radical Operations for the Cure of Carcinoma of the Breast. Ann Surg 1907; 46:1-19; PMID:17861990; http://dx.doi.org/10.1097/00000658-190707000-00001
6. Orr TG Jr. An incision and method of wound closure for radical mastectomy. Ann Surg 1951; 133:565-6; PMID:14819996
7. Péloquin A, Poljicak M, Falardeau M, Gravel D, Moïsescu R, Péloquin L. Cancer of the breast: a study of 1520 consecutive patients operated on between 1960 and 1980. Can J Surg 1991; 34:151-6; PMID:1888359
8. Sporn MB. The war on cancer. Lancet 1996; 347:1377-81; PMID:8637346; http://dx.doi.org/10.1016/S0140-6736(96)91015-6 (Pubitemid 26147937)
9. Gatenby RA. A change of strategy in the war on cancer. Nature 2009; 459:508-9; PMID:19478766; http://dx.doi.org/10.1038/459508a
10. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2:574-7; PMID:8616718; http://dx.doi.org/10.1038/nm0596-574 (Pubitemid 26150685)
11. Scholz C, Wieder T, Stärck L, Essmann F, Schulze- Osthoff K, Dörken B, Daniel PT. Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 2005; 24:1904-13; PMID:15674346; http://dx.doi.org/10.1038/sj.onc. 1208233 (Pubitemid 40462792)
12. Baldwin AS. Regulation of cell death and autophagy by IKK and NF-kB: critical mechanisms in immune function and cancer. Immunol Rev 2012; 246:327-45; PMID:22435564; http://dx.doi.org/10.1111/j.1600-065X.2012.01095.x
13. Baum V, Bühler P, Gierschner D, Herchenbach D, Fiala GJ, Schamel WW, Wolf P, Elsässer-Beile U. Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy 2013; 5:27-38; PMID:23256796; http://dx.doi.org/10.2217/imt.12.136
14. Mocikat R, Braumüller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis J, Mailhammer R, Riethmüller G, et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T-cell responses. Immunity 2003; 19:561-9; PMID:14563320; http://dx.doi.org/10.1016/S1074-7613(03)00264-4 (Pubitemid 37311437)
15. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347
16. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100:690- 7; PMID:12209608; http://dx.doi.org/10.1002/ijc.10557 (Pubitemid 34832980)
17. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, et al.; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783-91; PMID:23020162; http://dx.doi.org/10.1056/NEJMoa1209124
18. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
19. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al.; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138- 48; PMID:23228172; http://dx.doi.org/10.1056/NEJMoa1209096
20. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367:435-44; PMID:22853014; http://dx.doi.org/10.1056/NEJMoa1201622
21. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
22. Müller-Hermelink N, Braumüller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, et al. TNFR1 signaling and IFN-? signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008; 13:507- 18; PMID:18538734; http://dx.doi.org/10.1016/j.ccr.2008.04.001 (Pubitemid 351763899)
23. Ziegler A, Heidenreich R, Braumüller H, Wolburg H, Weidemann S, Mocikat R, Röcken M. EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood 2009; 113:3494-502; PMID:19188665; http://dx.doi.org/10.1182/blood-2008-08-175109
24. Egeter O, Mocikat R, Ghoreschi K, Dieckmann A, Röcken M. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 2000; 60:1515-20; PMID:10749115 (Pubitemid 30183417)
25. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207:651-67; PMID:20156973; http://dx.doi.org/10.1084/jem.20091921
26. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637-50; PMID:20156971; http://dx.doi.org/10.1084/jem.20091918
27. Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, Fulton A, Tamada K, Strome SE, Antony PA. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 2013; 190:4899-909; PMID:23536636; http://dx.doi.org/10.4049/jimmunol.1300271
28. Wieder T, Braumüller H, Kneilling M, Pichler B, Röcken M. T cell-mediated help against tumors. Cell Cycle 2008; 7:2974-7; PMID:18838866; http://dx.doi.org/10.4161/cc.7.19.6798
29. Sen S, D'Incalci M. Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett 1992; 307:122-7; PMID:1639187; http://dx.doi.org/10. 1016/0014-5793(92)80914-3
30. Boujrad H, Gubkina O, Robert N, Krantic S, Susin SA. AIF-mediated programmed necrosis: a highly regulated way to die. Cell Cycle 2007; 6:2612- 9; PMID:17912035; http://dx.doi.org/10.4161/cc.6.21.4842 (Pubitemid 350224042)
31. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dörken B, Daniel PT. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor- ligand interaction and occurs downstream of caspase- 3. Blood 2001; 97:1378-87; PMID:11222383; http://dx.doi.org/10.1182/blood.V97.5.1378 (Pubitemid 32183762)
32. Roca FJ, Ramakrishnan L. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 2013; 153:521-34; PMID:23582643; http://dx.doi.org/10.1016/j.cell.2013.03.022
33. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-9; PMID:16946036; http://dx.doi.org/10.1126/science.1129003 (Pubitemid 44547756)
34. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565- 70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
35. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, et al. Senescence surveillance of premalignant hepatocytes limits liver cancer development. Nature 2011; 479:547-51; PMID:22080947; http://dx.doi.org/10.1038/nature10599
36. Finn OJ. Cancer immunology. N Engl J Med 2008; 358:2704-15; PMID:18565863; http://dx.doi.org/10.1056/NEJMra072739
37. Gimbrone MA Jr., Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136:261- 76; PMID:5043412; http://dx.doi.org/10.1084/jem.136.2.261
38. Folkman J, Hochberg M. Self-regulation of growth in three dimensions. J Exp Med 1973; 138:745- 53; PMID:4744009; http://dx.doi.org/10.1084/jem.138.4.745
39. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903-7; PMID:18026089; http://dx.doi.org/10.1038/nature06309 (Pubitemid 350231320)
40. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25:585-621; PMID:13905658; http://dx.doi.org/10. 1016/0014-4827(61)90192-6
41. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007; 130:223-33; PMID:17662938; http://dx.doi.org/10.1016/j.cell.2007.07. 003 (Pubitemid 47081143)
42. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132:363-74; PMID:18267069; http://dx.doi.org/10.1016/ j.cell.2007.12.032 (Pubitemid 351191995)
43. Santra MK, Wajapeyee N, Green MR. F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 2009; 459:722- 5; PMID:19412162; http://dx.doi.org/10.1038/nature08011
44. Kodama R, Kato M, Furuta S, Ueno S, Zhang Y, Matsuno K, Yabe-Nishimura C, Tanaka E, Kamata T. ROS-generating oxidases Nox1 and Nox4 contribute to oncogenic Ras-induced premature senescence. Genes Cells 2013; 18:32-41; PMID:23216904; http://dx.doi.org/10.1111/gtc.12015
45. Benhamed M, Herbig U, Ye T, Dejean A, Bischof O. Senescence is an endogenous trigger for microRNAdirected transcriptional gene silencing in human cells. Nat Cell Biol 2012; 14:266-75; PMID:22366686; http://dx.doi.org/10.1038/ ncb2443
46. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600- associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436:720-4; PMID:16079850; http://dx.doi.org/10.1038/nature03890 (Pubitemid 41117276)
47. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguría A, Zaballos A, Flores JM, Barbacid M, et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436:642; PMID:16079833; http://dx.doi.org/10.1038/436642a (Pubitemid 41117258)
48. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) 2012; 4:159-65; PMID:22394614
49. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011; 11:503-11; PMID:21701512; http://dx.doi.org/10.1038/nrc3057
50. Haferkamp S, Borst A, Adam C, Becker TM, Motschenbacher S, Windhövel S, Hufnagel AL, Houben R, Meierjohann S. Vemurafenib induces senescence features in melanoma cells. J Invest Dermatol 2013; 133:1601-9; PMID:23321925; http://dx.doi.org/10.1038/jid.2013.6
51. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17:320- 9; PMID:21383745; http://dx.doi.org/10.1038/nm.2328
52. Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010; 18:485-98; PMID:21035406; http://dx.doi.org/10.1016/j.ccr.2010.10.002
53. Reimann M, Lee S, Loddenkemper C, Dörr JR, Tabor V, Aichele P, Stein H, Dörken B, Jenuwein T, Schmitt CA. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1- dependent senescence. Cancer Cell 2010; 17:262- 72; PMID:20227040; http://dx.doi.org/10.1016/j.ccr.2009.12.043
54. Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, Lechel A, Rudolph KL, Langer R, Slotta-Huspenina J, et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 2013; 23:93-106; PMID:23273920; http://dx.doi.org/10.1016/j.ccr.2012.11.014
55. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71:1263-71; PMID:21303976; http://dx.doi.org/10.1158/0008-5472.CAN-10-2907
56. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10:205; PMID:23034130; http://dx.doi.org/10.1186/1479-5876-10-205
57. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494:251-5; PMID:23302800; http://dx.doi.org/10.1038/nature11814
58. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 1985; 318:665-7; PMID:3001529; http://dx.doi.org/10.1038/318665a0 (Pubitemid 16172416)
59. Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, Fojo AT, Bates SE. Analyzing the pivotal trial that compared sunitinib and IFN-a in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res 2012; 18:2374-81; PMID:22344231; http://dx.doi.org/10.1158/1078- 0432.CCR-11-2275